Year: 2021

MORRISVILLE, N.C., Dec. 29, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) announced today that United Therapeutics Corporation (UTC) has filed a stipulation of partial judgment with respect to U.S. Patent No. 9,604,901 (‘901 patent) in the on-going litigation under the Hatch-Waxman Act (Hatch-Waxman). Under the stipulation of partial judgment, UTC has agreed to the entry of judgment of Liquidia’s non-infringement of the ’901 patent based on the Court’s construction of certain terms in the patent. UTC has preserved its appellate rights with respect to the ‘901 patent in the event the Court’s construction of those terms is reversed. With this stipulation of partial judgment, only U.S. Patent No. 9,593,066 (‘066 patent) will now serve as a basis for the on-going regulatory stay for final approval of YUTREPIA™ (treprostinil)...

VANCOUVER, British Columbia, Dec. 29, 2021 (GLOBE NEWSWIRE) — Eden Empire Inc. (CSE: EDEN) (the “Company” or “Eden Empire“) is pleased to announce that it has closed the third tranche of its previously announced C$500,000 private placement (the “Private Placement”).The third tranche consisted of 4,700,000 Units (defined below) for gross proceeds of C‎$235,000‎ (the “Third Tranche Private Placement”). Each Unit in the Private Placement is comprised of one common share of the Company (a “Share”) at a price of C$0.05 per Share, and one common share purchase warrant (a “Warrant”, and together with a Share, a “Unit”). ‎Each Warrant entitles the holder thereof to acquire one Share of the Company at a price of ‎C$0.10 for a period of 36 months from the date of issuance (the “Warrant Expiry Date”). If the daily...

Las Vegas, NV, Dec. 29, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Hestia Insight Inc. (OTC Markets: HSTA) (“Hestia Insight” and the “Company”), a Company focused on the development of novel technologies in the healthcare and biotech sectors, today announced its execution of a Memorandum of Understanding with General Data Collection Ltd. (“GDC”), pursuant to which Hestia Insight and GDC have agreed in principle to enter into license agreements whereby GDC would grant to Hestia Insight, on an exclusive, non-revocable, royalty-free, and perpetual basis, licenses in certain of GDC’s technologies relating to the treatment of mental health conditions using electromagnetic brain pulse (“EMBP™”) protocols and products (collectively, the “Technologies”), in order for Hestia Insight to exclusively develop, make,...

ATLANTA, Dec. 29, 2021 (GLOBE NEWSWIRE) — Chart Industries, Inc. (NYSE: GTLS), a leading diversified global manufacturer of highly engineered equipment for the industrial gas and clean energy industries, was awarded over $120 million of orders for four liquefaction projects, with four different customers over the past week. Additionally, this past week we have received releases on engineering work (Limited Notice to Proceed) on two of the big LNG export terminal projects expected to proceed to Final Investment Decision in 2022. Highlights of the four liquefaction project awards include:Hydrogen liquefier: A 15 ton per day (“TPD”) hydrogen liquefier to be built in North America with a new hydrogen liquefaction customer. This is our fourth hydrogen/helium liquefaction order of the year in 2021, with those four orders totaling approximately...

Selskabsmeddelelse Nr. 09/2021 Indeholder intern viden ERRIA har dd. har overtaget det vietnamesiske selskab Mermaid Maritime Vietnam JSC (”Mermaid”).Mermaid blev etableret i 2004 og selskabets primære aktiviteter er salg og service af rednings-og brandslukningsudstyr til marine og offshore. Mermaid er salgs- og service partner for Viking Lifesaving Equipment A/S og har hovedkontor og workshop i Vung Tau i det sydlige Vietnam og workshop i Hai Phong i det nordlige Vietnam. Selskabets kunder omfatter store offshore selskaber, skibsværfter, lokale rederier samt internationale rederier med skibe der anløber Vietnamesiske havne. ”Jeg er glad for at byde de ansatte, kunder og interessenter i Mermaid velkommen til Erria-familien. Mermaid er en attraktiv og succesrig virksomhed med en gennemprøvet forretningsmodel og en lang historie i...

Offer, buyback, cut-off price, pro rata and yield are presented in the table below:ISIN Offer mill. DKK (nominal) Buy-back mill. DKK (nominal) Cut-off price Pro rata Yield99 23997 DGB 0.25% 15/11/2022 220 0 – – –Total 220 0      

Bids, sales, stop-rates and prices are presented in the table below:      ISIN Bid Mill. kr. (nominal) Sale Stop-rate (per cent) Pro-rata Price98 18429 DKT 01/03/22 I 300 100 -0.675 100 % 100.107098 18502 DKT 01/06/22 II 0 0 – – –98 18692 DKT 01/09/22 III 0 0 – – –98 18775 DKT 01/12/22 IV 0 0 – – –Total 300 100      The sale will settle 3 January 2022.

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the systemic exposure of docetaxel after treating solid tumors with NanoZolid®-docetaxel is low and that the study demonstrated activity in both injected lesions and in systemic inflammatory markers. The results support further development of NanoZolid®-docetaxel. In October 2021, LIDDS announced the closing of the NZ-DTX-001 Phase I study. It was demonstrated that NanoZolid® in combination with docetaxel was safe and well tolerated, reaching the primary endpoint of the trial. After further analysis it is also concluded that the systemic NanoZolid®-docetaxel exposure is low and that activity in injected lesions is observed. Patients receiving docetaxel showed activation of systemic inflammatory biomarkers including IFN-gamma, CXCL9 and CXCL10. These molecules are considered important...